

# Dr. Earl Ettienne

Howard University  
Associate Professor  
Clinical and Administrative Pharmacy Sciences  
(202) 806-4209  
earl.ettienne@Howard.edu

## Professional Positions

Assistant Dean for Graduate Programs and Industrial Partnerships, Howard University, Pharmacy/Graduate School. (January 2023 - Present).

Associate Professor, Howard University College of Pharmacy, Clinical and Administrative Pharmacy Sciences. (July 1, 2018 - Present).

Assistant Professor, Howard University College of Pharmacy, Clinical and Administrative Pharmacy Sciences. (January 9, 2012 - June 30, 2018).

Clinical & Administrative Pharmacy Consultant, Clinical Pharmacy Associates, Clinical Pharmacy Operations. (January 3, 2011 - January 3, 2012).

Senior Supervisor-Pharmacy Operations and Government Affairs, CVS/Caremark, Area Office. (July 2003 - December 2010).

District Manager, CVS/Caremark, Store Operations. (July 1999 - June 2003).

Regional Healthcare Manager, CVS/Caremark, Pharmacy. (January 1997 - June 1999).

Pharmacy Supervisor, CVS Pharmacy, Pharmacy. (January 1995 - July 1997).

Pharmacy Department Manager, CVS Pharmacy, Pharmacy. (January 1994 - January 1995).

Pharmacy Team Leader, CVS Pharmacy, Pharmacy. (July 1992 - January 1994).

Pharmacy Resident, The Mt Sinai Hospital, Pharmacy. (June 1991 - June 1992).

## Education

Principles of Clinical Pharmacology (Certificate in Clinical Pharmacology). National Institutes of Health, Bethesda, MD, United States. August 2023 - June 2024.

Certificate in Health Disparities: A Translational Research Approach (Certificate Training). NIH/University of Puerto Rico, Bethesda, MD, United States. January 2016 - April 2016.

Certificate in Entrepreneurship (Certificate in Entrepreneurship). Howard University School of Business, Washington, DC, United States. August 2014 - October 2014.

LPD, Law and Policy, Econometric Analysis, Lobbying, Strategy. Northeastern University, 2012.

MBA, General (Marketing and Strategy), Strategy. Loyola University, 2000.

Finance (Certificate). Bryant University, Smithfield, RI, United States. January 1996 - September 1996.

Residency in Clinical and Administrative Pharmacy (Residency). The Mt. Sinai Medical Center, New York, NY, United States. July 1, 1991 - June 30, 1992.

BSc, Pharmacy. Howard University, 1991.

## **Licensures and Certifications**

Evidence Based Teaching Using Generative AI, Howard University Center for Education Teaching and Learning (CETLA). (May 2, 2025 - Present).

Initiating Buprenorphine, American Pharmacist Association. (October 18, 2024 - Present).

Distance Learning Teaching Certification, Howard University. (January 13, 2020 - Present).

Pharmacy Based Immunization Delivery, American Pharmacists Association. (October 2018 - Present).

Clinical Investigator Training, Food and Drug Administration. (November 2017 - Present).

Medicare Advantage and Prescription Drug Plan Certification, Center for Medicare and Medicaid. (September 2016 - Present).

Pharmacist, District of Columbia. (January 1, 1994 - February 28, 2027).

Pharmacist/Vaccine Certified, State of Maryland. (July 6, 1991 - October 31, 2026).

## **Professional Memberships**

Howard University Pharmacy Alumni Association. (March 2020 - Present).

Regulatory Affairs Professional Society. (2018 - Present).

Academy Health. (2017 - Present).

The Pharmacy Quality Alliance. (2016 - Present).

American Association of Colleges of Pharmacy. (2013 - Present).

National Community Pharmacists Association. (2013 - Present).

American Pharmacist Association. (1991 - Present).

International Society for Pharmacoeconomics and Outcomes Research. (2013 - 2020).

Maryland Health Quality and Cost Council. (2012 - 2013).

Washington DC, Pharmacy and Therapeutics Committee. (2007 - 2013).

District of Columbia Economic Advisory Council. (2004 - 2010).

Woodstock Business Conference. (2005 - 2008).

Loyola University Executive Alumni Association. (2001 - 2007).

DC Healthy Families. (1998 - 2007).

Health Families DC. (1997 - 2005).

## **Awards and Honors**

Excellence in Teaching Award, Howard University College of Pharmacy. (July 1, 2025).

Ten Years of Transformative Impact, Howard University. (June 20, 2025).

Cultivate Leadership Award, Young Black Pharma. (November 2, 2024).

Outstanding Leadership & Excellence Award, HUPIF Fellows. (June 20, 2024).

Van Der Horst Sacrificial Leadership Award, Howard University College of Pharmacy. (May 8, 2024).

Cardinal GenerationRX Champions Award, Washington DC Pharmacists Association. (2018).

Legacy by Decades Award, Howard University College of Pharmacy Alumni Association. (May 2017).

Most Outstanding Presentation in the Area of Translational and Clinical Sciences, Howard University. (April 2017).

Best Overall Poster Presentation, The Center for Computational Biology and Informatics Howard University College of Medicine. (2016).

Cisco Excellence Award and Best Public Safety App, AT&T Hackathon. (2016).

Most Outstanding Presentation by a Junior Faculty Researcher, Howard University. (2014).

Paragon Award for Operational Excellence, CVS/Caremark. (2005).

Excellence in Execution Award, CVS/Caremark. (2003).

Trailblazer Award, National Press Club. (2000).

Howard Bovell Excellence in Pharmacy Award, Howard University College of Pharmacy. (1991).

Mylan Pharmaceuticals Excellence in Pharmacy Award, Howard University College of Pharmacy. (1991).

Upjohn Pharmaceutical Sciences Award, Howard University College of Pharmacy. (1991).

## **Media Appearances and Interviews**

"Pharmacies, Drugmakers on Edge for Rollout of US Drug Price Cuts," Bloomberg Law. (August 29, 2024).

"We Center Blackness: Howard, Diversity and Diaspora," WHUT. (November 2023).

"HBCUS Are Essential to Improving Diversity in Pharmacy," Pharmacy Times. (February 2023).

"Howard University's equity focus advances translation, invites industry.," Biocentury Biotech Industry Insight Magazine Article April 2022. (May 2, 2022).

"<https://www.bms.com/tomorrows-innovators.html>," <https://www.bms.com/tomorrows-innovators.html>. (2021).

"In Healthcare We Have Trust," Howard Magazine. (October 2021).

"Why Pharmacies Overcharge," CNBC Web. (August 26, 2021).

"Beyond the Pharmacy Counter: Howard University's College of Pharmacy gives Students Firsthand Experience in a Field with Endless Possibilities," Diversity in Action. (2020).

"At Mostly Black Church, Pence Tells Community Leaders Floyd's Death 'Shocked the Conscience of a Nation'" The Washington Post, June 5, 2020  
<https://www.washingtonpost.com/religion/2020/06/05/pence-church-george-floyd-protests/>," Washington Post. (2020).

"Pastor tells Mike Pence leaders need the 'right tone' during listening session over George Floyd's death" USA Today, June 5, 2020," USA Today. (2020).

"Doctor Vision Interview," Praise 94.5 Radio Station, Beaufort, SC 29901-1872. (2020).

"Innovation in Pharmacy-- Health Policy," Maryland Public Television. (2020).

"Howard University, FDA and GlaxoSmithKline Announce Innovative Regulatory Affairs and Policy Fellowship Program" Howard University Newsroom, March 5, 2018," "Howard University, FDA and GlaxoSmithKline Announce Innovative Regulatory Affairs and Policy Fellowship Program" Howard University Newsroom, March 5, 2018. (March 5, 2018).

"Opioid Epidemic Hits D.C. Hard" The Washington Informer, November 8, 2017  
<http://washingtoninformer.com/opioid-epidemic-hits-d-c-hard/>," "Opioid Epidemic Hits D.C. Hard" The Washington Informer, November 8, 2017 <http://washingtoninformer.com/opioid-epidemic-hits-d-c-hard/>. (November 8, 2017).

"The Opioid Crisis" Rock Newman Show, WHUT TV, November 1, 2017," WHUT TV. (November 1, 2017).

"Howard University to Hold Major Symposium on National Opioid Crisis" Howard University Newsroom, October 30, 2017," Howard University. (October 30, 2017).

"Historically Black Colleges and Universities Equity, Healthcare Top Black Legislative Agenda"; Baltimore Afro-American Newspaper November 24, 2012," "Historically Black Colleges and Universities Equity, Healthcare Top Black Legislative Agenda"; Baltimore Afro-American Newspaper November 24, 2012. (November 24, 2012).

"Medicare Part D: Implementation of the New Drug Benefit"; Kaiser Family Foundation: Tracking Medicare and Prescription Drug Plans #82 April 5, 2006," "Medicare Part D: Implementation of the New Drug Benefit"; Kaiser Family Foundation: Tracking Medicare and Prescription Drug Plans #82 April 5, 2006. (2006).

"Medicare Part D: A View from the Field"; Chain Drug Review, March 27, 2006," Chain Drug Review. (March 2006).

"Giving Part D A Spin" Washington Post September 27, 2005," Washington Post. (2005).

## Publications

- Ettienne, E. B. (2025). Disorders of gut-brain interaction are a new challenge of our increasingly complex society, with worldwide repercussions. *World Journal of Clinical Pediatrics*, 14(2). 10305 Ackerly Terrace
- Ettienne, E. B. (2025). African minors' health challenges are comparable to those in the rest of the world. *World Journal of Clinical Pediatrics*, 14(2). 10305 Ackerly Terrace
- Moore, J., IHEME, N., Rebold, N. S., Kusi, H., Mere, C., Nwaogwugwu, U., Ettienne, E. B., Chaijamorn, W., Rungkitwattanakul, D. (2025). Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. *Pharmacy*, 13(2).  
<https://doi.org/10.3390/pharmacy13020046>
- Moore, J., IHEME, N., Rebold, N., Kusi, H., Mere, C., Nwaogwugwu, U., Ettienne, E., Chaijamorn, W., Rungkitwattanakul, D. (2025). Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. *Pharmacy (Basel, Switzerland)*, 13(2).
- Ettienne, E. (2025). Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review. *Expert Opinion on Pharmacotherapy*, 1-9.  
<https://www.tandfonline.com/doi/full/10.1080/14656566.2025.2475184?scroll=top&needAccess=true>
- Awuonda, M., Alem, G., Reddy, M., Daftary, M., Wingate, L., Ettienne, E. (2024). Predictors of using Pharmacists as a Medication Safety Information Resource among Women of Reproductive age. *Drugs Healthcare and Patient Safety*, 16(24), 125-132.  
<https://www.tandfonline.com/doi/full/10.2147/DHPS.S412786>
- Ettienne, E. (2024). Deception and fraud in the justification of 'Pediatric Drug Development'. A challenge at the interface of medicine and law. *Journal of Law and Medicine*, 31(3), 635-644.
- Ettienne, E. (2024). Pharmacogenomics and pediatric drug development: science and political power. A narrative review. *Expert Opinion On Pharmacotherapy*, 25(18), 2367-2373.
- Barsh, D., Awuonda, M., McCants, T., Daftary, M., Wingate, L., Ettienne, E., Chapman, E., Lyons, J. (2024). National trends in reported past year opioid misuse among black women. *Journal of the National Medical Association*, 116(3), 271-282.  
<https://doi.org/10.1016/j.jnma.2024.01.027>
- Ettienne, E. (2024). Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals. *World Journal of Methodology*, 14(2).  
<https://www.wjgnet.com/2222-0682/full/v14/i2/92371.htm>
- Ettienne, E. (2024). *Pharmacogenomic Profiles of Patients with Sickle Cell Disease*. RCMJ Conference Proceedings 2024.
- Ettienne, E. (2023). *Pediatric Medication Studies: A New Challenge for Institutional Review Boards, Ethics Committees*. Cranbury New Jersey: MJH Life Sciences.
- Ettienne, E. (2023). Covid19 and Africans in the Diaspora: Rhetoric, Face and Unintended Consequences. *African Journal of Rhetoric*, 15(1). [https://journals.co.za/doi/full/10.10520/ejcaar\\_rhetoric\\_v15\\_n1\\_a1](https://journals.co.za/doi/full/10.10520/ejcaar_rhetoric_v15_n1_a1)

- Ettienne, E. (2023). Trinidad and Tobago, Covid 19, and Point-of-View Language: A Case for Public Diplomacy. *African journal of Rhetoric*, 15. [https://journals.co.za/doi/abs/10.10520/ejcaar\\_rhetoric\\_v15\\_n1\\_a17](https://journals.co.za/doi/abs/10.10520/ejcaar_rhetoric_v15_n1_a17)
- Ettienne, E., Ofoegbu, A. (2023). Pharmacogenomics and Morphine. *The Journal of Clinical Pharmacology*, 61(9), Pages 1149-1155. <http://dx.doi.org/10.1002/jcph.1873>
- Ettienne, E. (2023). *Have Children Truly Ever Been 'Therapeutic Orphans?* Cranbury New Jersey: MJH Life Sciences.
- Ettienne, E. (2023). "Pediatric" drug studies might be the largest abuse in medical research in history. it is time for lawyers to step in. *Journal of Law and Medicine*, 30(1), 131-154. [https://www.safelylit.org/citations/index.php?fuseaction=citations.viewdetails&citationIds\[\]=citjournalarticle\\_758516\\_12](https://www.safelylit.org/citations/index.php?fuseaction=citations.viewdetails&citationIds[]=citjournalarticle_758516_12)
- Ettienne, E. (2023). "Pediatric" Drug Studies Might Be the Largest Abuse in Medical Research in History. It Is Time for Lawyers to Step In. *Journal of Law and Medicine*, 30(1), 131-154.
- Mayaka, R. K., Awuonda, M. K., Ettienne, E., Daftary, M., Wingate, L., Unonu, J. (2023). A Cross-Sectional Survey on the Post-Pandemic Acceptability of Pharmacist-Delivered Telehealth Services Among HCV-HIV Patients. *Inquiry: The Journal of Health Care Organization, Provision, and Financing*, 60. <https://doi.org/10.1177/00469580231171338>
- Alem, G., Awuonda, M., Haastrup, D., Anyiwo, A., Daftary, M., Wingate, L., Ettienne, E. (2022). Evaluation of knowledge of the new Pregnancy and Lactation Labeling Rule among pharmacists and physicians. *Journal of the American Pharmacists Associations*, 62(2), 427-431. <https://doi.org/10.1016/j.japh.2021.10.012>
- Rose, K., Ettienne, E., Grant-Kels, J. M., Striano, P., Neubauer, D., Tanjinatus, O. (2022). Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies. *Expert Review of Neurotherapeutics*, 22(3), 209-219. <http://dx.doi.org/10.1080/14737175.2022.2045953>
- Alzahrani, M. S., Maneno, M. K., Daftary, M., Wingate, L., Ettienne, E., Howell, C. (2021). Patterns of Hepatitis C-Related Inpatient Mortality in the United States in the Era of Direct-Acting Antivirals. *Journal of gastroenterology and hepatology research*, 9(3), 3169-3175.
- Rose, K., Grant-Kels, J. M., Ettienne, E., Tanjinatus, O., Striano, P., Neubauer, D. (2021). Comment on: A review of the experience with pediatric written requests issued for oncology drug products. *Pediatric Blood & Cancer*, 68(8). <http://dx.doi.org/10.1002/pbc.28972>
- Rose, K., Tanjinatus, O., Grant-Kels, J., Ettienne, E., Striano, P. (2021). Letter to the Editor: Delayed Presentation of Non-COVID-19 Patients During the COVID-19 Pandemic Is Not Limited to Children. *Rambam Maimonides Medical Journal*, 12(3), e0026. <http://dx.doi.org/10.5041/rmmj.10447>
- Rose, K., Tanjinatus, O., Grant-Kels, J. M., Ettienne, E., Striano, P., Neubauer, D. (2021). Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development. *The Journal of Clinical Pharmacology*, 61(6), 736-739. <http://dx.doi.org/10.1002/jcph.1806>
- Rose, K., Tanjinatus, O., Ettienne, E. (2021). The Term "Juvenile Idiopathic Arthritis (JIA)" is Misleading. It Will not be Sufficient to Just Replace this Term. *Pharmaceutical Medicine*, 35(3), 143-146. <http://dx.doi.org/10.1007/s40290-021-00379-8>

- Rose, K., Grant-Kels, J., Ettienne, E., Tanjinatus, O., Striano, P., Neubauer, D. "Comment on: A review of the experience with pediatric written requests issued for oncology drug products." *Young patients with malignancies need reasonable studies with therapeutic intention...* Authorea, Inc... <http://dx.doi.org/10.22541/au.161280832.22407928/v1>
- Ettienne, E., Ofoegbu, A., Maneno, M. K., Briggs, J., Ezeude, G., Williams, S., Walker, C., Chapman, E. (2019). Pharmacogenomics and OUD: Clinical Decision Support in an African American Cohort. *Journal of the National Medical Association*.
- Malhani, M., Maneno, M., Gabriel, M., Wingate, M., Ettienne, E. (2019). *The Association between Hospital Ownership Type and Health Information Exchange in the Emergency Departments* (6th ed., vol. 15, pp. e31). Elsevier BV. <http://dx.doi.org/10.1016/j.sapharm.2019.04.027>
- Wingate, L., Stubbs, K., Ahmed, I., Mayaka, R. K., Maneno, M. K., Ettienne, E., Elekwachi, O., Clarke-Tasker, V. (2018). The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks. *International journal of environmental research and public health*, 15(10).
- Wingate, L. T., Stubbs, K., Ahmed, I., Mayaka, R. K., Maneno, M. K., Ettienne, E., Elekwachi, O., Clarke-Tasker, V. (2018). The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks. *International Journal of Environmental Research and Public Health*, 15(10). <https://doi.org/10.3390/ijerph15102128>
- Alzahrani, M. S., Maneno, M. K., Daftary, M., Wingate, L., Ettienne, E. (2018). Factors Associated with Prescribing Broad-Spectrum Antibiotics for Children with Upper Respiratory Tract Infections in Ambulatory Care Settings. *Clinical medicine insights. Pediatrics*, 12, 1179556518784300. <https://journals.sagepub.com/doi/full/10.1177/1179556518784300>
- Alzahrani, M. S., Maneno, M. K., Daftary, M., Wingate, L., Ettienne, E. (2018). Factors Associated with Prescribing Broad-Spectrum Antibiotics for Children with Upper Respiratory Tract Infections in Ambulatory Care Settings. *Clinical Medicine Insights: Pediatrics*, 12, 1179556518784300. <http://dx.doi.org/10.1177/1179556518784300>
- Wingate, L., Awuonda, M., Ettienne, E. (2018). The Economic Impact of Shingles Vaccine Disparities Among Hispanics. *Value in Health*, 21(1), S142. <http://dx.doi.org/10.1016/j.jval.2018.04.983>
- Awuonda, M., Ettienne, E., Wingate, L., Wingate, L. (2018). *Impact of the Hitech Act's Incentive Program on the Adoption of Drug-Drug Interaction Alerts and Electronic Prescribing in the Ambulatory Care Setting* (vol. 21, pp. S178). Elsevier BV. <http://dx.doi.org/10.1016/j.jval.2018.04.1187>
- Ettienne, E., Ofoegbu, A., Awuonda, M., Wingate, L. B., Dunston, G. B., Kurian, P. B., Wilson, B. B., Nguyen, K. B., Ezeude, G., Augusto, J. (2017). Public choice theory and rhetoric: advancing pharmacogenomics through health policy in Africa. *African Journal of Rhetoric*, 9(1), 119-142.
- Wilson, B., Ettienne, E., Apprey, V., Ofoegbu, A., Abbas, M., Dunston, G., Saadatmand, F. (2017). Opioid Metabolizing Enzyme Allele Frequencies and Drug Use in a Cohort of African American Young Adults. *ARC Journal of Addiction*, 2(2), 4-9.
- Rashrash, M., Maneno, M., Wutoh, A., Ettienne, E., Daftary, M. (2017). Predictors of hepatitis C testing intention among African American Baby Boomers. *Journal of epidemiology and global health*, 7(2), 119-122.

- Warholak, T. L., Patel, M., Rosenthal, M., West-Strum, D., Ettienne, E., Nunlee-Bland, G., Nau, D., Hincapie, A. L. (2017). Patient perceptions of a pharmacy star rating model. *Journal of the American Pharmacists Association*, 57(3), 311-317.  
<http://dx.doi.org/10.1016/j.japh.2017.01.011>
- Ettienne, E., Chapman, E., Maneno, M., Ofoegbu, A., Wilson, B. F., Settles-Reaves, B., Clarke, M., Dunston, G., Rosenblatt, K. (2017). Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach. *Addictive behaviors reports*, 6, 8-14.
- Awuonda, M., Wutoh, A., Ettienne, E., Daftary, M., Daftary, M. (2017). Predictors of hepatitis C testing intention among African American Baby Boomers. *Journal of Epidemiology and Global Health*, 7(2), 119-122. <https://doi.org/10.1016/j.jegh.2016.12.005>
- Rashrash, M. E., Maneno, M. K., Wutoh, A., Ettienne, E., Daftary, M. (2016). An evaluation of hepatitis C knowledge and correlations with health belief model constructs among African American "baby boomers". *Journal of infection and public health*, 9(4), 436-42.
- Alem, G., Awuonda, M., Ettienne, E., Wingate, L. (2016). Serum Vitamin D Deficiency among African American Women in the United States. *Value in Health*, 19(3), A173.  
<http://dx.doi.org/10.1016/j.jval.2016.03.1452>
- Malhani, M.A., Awuonda, M., Ettienne, E., Wingate, L. (2016). *Factors Affecting Adoption of Computerized Physician Order Entry System* (3rd ed., vol. 19, pp. A274). Elsevier BV.  
<http://dx.doi.org/10.1016/j.jval.2016.03.1954>
- Rashrash, M., Maneno, M., Wutoh, A., Ettienne, E., Daftary, M. (2015). An Evaluation of Hepatitis C Knowledge and Correlations with Health Belief Model Constructs among African American "baby boomers". *Journal of Infection and Public Health*.
- Ettienne, E. B., Godwin, O., Brown, L.M. (2015). Cost- effectiveness analysis of nevirapine vs. Ritonavir-boosted lopinavir in hiv-infected children with peripartum nevirapine exposure, in resource-constrained areas from a payer's perspective. *Value in Health*, 18(3), A240.  
<http://dx.doi.org/10.1016/j.jval.2015.03.1395>
- Ettienne, E., Ofoegbu, A., Wingate, L., Dunston, G., Augusto, J. (2015). Pharmaceutical Care Coordination and Genomics in Emerging Markets: A Business Case for Ghana. *International Academy of Business Review*, 1(1), 60-70.
- Akiyode, O., Nguyen, A., Augusto, J., Wiley, K., Ettienne, E. (2015). Adopting Physical Activity Lifestyle in a Pharmacy Curriculum. *Pharmacy Education*, 15(1), 14-16.
- Weaver, S., Oji, V., Ettienne, E., Stolpe, S., Awuonda, M. (2014). Hybrid E-Learning Approach to Health Policy. *Currents in Pharmacy Teaching and*, 6(2), 313-322.

## Presentations

- Ettienne, E. B. (Presenter/Panelist), Bridging Healthcare Communities, "It's in Our Genes: Genetics and the Future of Precision Medicine", "Black Health Connect/ IndyGeneUS, National Housing Center Auditorium, Washington, DC. (June 27, 2025).
- Ofoegbu, A., Uprety, R., Elesho, R., Ogini, F., Sookraj, K., Berkley, A., Hicks, D., Omilana, O., Ettienne, E., Chapman, E. C., Howard University Research Month, "The Impact of Discordant Health Insurance Policies on Health Care Provider Reimbursement for Opioid Use Disorder Treatment," Howard University, Blackburn Center, Washington, DC, United States. (April 22, 2025).
- Ofoegbu, A., Uprety, R., Elesho, R., Ogini, F., Sookraj, K., Ettienne, E., Chapman, E. C., RCMI Annual Meeting, "Impact of Insurance Policy on Opioid Use Disorder Management," RCMI, Bethesda Children's Museum, Bethesda, MD, United States. (March 17, 2025).
- Ettienne, E., Ethiopian Pharmacists and Pharmaceutical Scientists in Diaspora (EPPAD) Annual Meeting, "The Role of Pharmacy Benefit Managers (PBM's) Transparency Reducing Disparities In Access to Specialty Oncology Drugs for Minority Patients," Ethiopian Pharmacists and Pharmaceutical Scientists in Diaspora (EPPAD), Holiday Inn Hotel & Conference Center, Alexandria, VA, United States. (November 2024).
- Ettienne, E., African Association of Rhetoric 10th Biennial Conference, "Pharmacogenomics and Public Policy: A Government's Response and its Implications for African Development," University of Ghana, Accra, Ghana. (July 4, 2024).
- Weaver, S. (Presenter), Miller, C. (Author), Ofoegbu, A. (Author), Ettienne, E. (Author), Wingate, L. (Author), RCMI Annual Meeting, "Pharmacogenomic Profiles of patients with Sickle Cell Disease," RCMI, Bethesda Marriott Conference Center, Bethesda, MD, United States. (April 2024).
- Ofoegbu, A., Ettienne, E., Chapman, E., Howard University Research Month, "The Impact of Prior Authorizations on Treatment Outcomes for African American OUD Patients in Washington D.C.," Howard University, Howard University IRB, Washington, DC. (April 26, 2024).
- Ettienne, E. (Presenter/Fellow Adviser), DIA Medical Affairs and Scientific Communication Forum, "Assessing the Utilization and Impact of the Medical Information and Global Labeling Management Collaborative Tool," Disney Coronado Springs Resort, Orlando, FL, United States. (March 2024).
- Ettienne, E. (Presenter/Fellow Adviser), Muhammed, M. (Fellow/Presenter), American Pharmacists Association, "Evaluating the Activity Level of Corporate and Medical Social Media Accounts of Pharmaceutical Companies," Howard University, American Pharmacist Association, Orlando, FL, United States. (March 2024).
- Weaver, S. (Presenter), Miller, C. (Author), Pitia, M. (Author), Wingate, L. (Author), Ettienne, E. (Author), Diaz, S. (Author), Taylor, J. (Author), APhA Annual Meeting, "Evaluation of the Health Related Quality of Life using the ASCQ ME Questionnaire in Patients with Sickle Cell Disease," APhA, Convention Center, Orlando, FL, United States. (March 2024).
- Ettienne, E. (Presenter/Faculty Adviser), American Society of Health-System Pharmacists® (ASHP) Annual Meeting, "Comparing the Presence of Corporate versus Medical Social Media Accounts of Pharmaceutical Companies," Howard University, Anaheim Convention Center, Anaheim, CA, United States. (December 2023).

Miller, C. (Presenter), Ofoegbu, A. (Author), Ettienne, E. (Author), Wingate, L. (Author), Weaver, S. (Author), ASHP Midyear Meeting, "Comprehensive pharmacogenomic profiling of patients living with Sickle Cell Disease (SCD) in the United States.," ASHP, Anaheim Convention Center, Anaheim, CA, United States. (December 2023).

Ettienne, E., College of Pharmacy 2023 Faculty and Staff Retreat, "Team Building with Cultural Considerations," Howard University College of Pharmacy, Marriott, Oxon Hill, MD, United States. (May 2023).

Ettienne, E., American Association of Colleges of Pharmacy-AACP Innovate 2023, "Applying Implementation Science to Pharmacy Practice Research: PGx-Guided Clinical Decision Support in Improving OUD Outcomes: A Hybrid Effectiveness-implementation Model Approach.," AACP, AACP Innovate Meeting Orlando Florida, Orlando, FL, United States. (February 2023).

Ettienne, E., AACP MidYear Meeting, "PGx-Guided Clinical Decision Support In Improving OUD Outcomes: A Hybrid Effectiveness-implementation Model Approach," AACP, Orlando Marriott, Orlando, FL, United States. (February 2023).

Ettienne, E. (Presenter), Responsible Conduct of Research, "Institutional Review Boards HIPAA Privacy Rule HITECH Act For Researchers," Howard University Research Office, Online, Washington, DC, United States. (September 19, 2022).

Ettienne, E. (Associate Professor), American Association of Colleges of Pharmacy Annual Meeting, "The Influence of Population Genetics and Psychosocial Factors on Pharmacotherapy Case Based Education. Where is the Meridian?," American Association of Colleges of Pharmacy, Gaylord Texan Resort and Convention Center, Gaylord, TX, United States. (July 2022).

Ettienne, E. B., YALI Fellows 2022 Lecture Series, "Brain Drain and Africa's Medical/Health Personnel Migrating to Richer and Industrialized Nations," US State Department, Howard University, Washington, DC, United States. (June 2022).

Ettienne, E., NIDA Genetics and Epigenetics Cross Cutting Conference, "The Role of Phase II Metabolic Enzymes and Drug Transporters on Buprenorphine Pharmacogenomics in Opioid Use Disorder Management," National Institutes of Health, National Institutes of Health, Bethesda, MD, United States. (March 2022).

Ettienne, E., Pharmaceutical Manufacturers and Researchers of America Biopharma Meeting, "Pathways to Success in Biopharma: Getting Your Foot in The Door," PhRMA, Online, Washington, DC, United States. (2021).

Ettienne, E. B., University of Utah Lecture Series, "Opioid Use Disorder, Race and Pharmacogenomics: Policy Implications from an African American Cohort' 11-18-2021," University of Utah, University of Utah, Salt Lake City, UT, United States. (November 17, 2021).

Ettienne, E. B., Howard University School of Law 18th Wiley A. Branton Symposium's, "'HBCUs, Public Health and the Law.," Howard University, Online, Washington, DC, United States. (October 4, 2021).

Ettienne, E., College of Dentistry 140th Anniversary Health Equity Symposium, "'Academic and Community Partnerships for Improvements in Health Outcomes of Minority Communities Through Health Literacy and Sustainable Community Development: Opioid Use Disorder,

- COVID, and Medication Therapy Management”, Howard University College of Dentistry, WHUT, Washington, DC, United States. (September 17, 2021).
- Ettienne, E., “Fireside Chat – Real Talk: COVID-19 Vaccine Uptake & Hesitancy.” Diaspora Health Coalition Community Vaccine Townhall, “Fireside Chat – Real Talk: COVID-19 Vaccine Uptake & Hesitancy.” Diaspora Health Coalition Community Vaccine Townhall, Diaspora Health Coalition, Online, Washington, DC, United States. (February 25, 2021).
- Ettienne, E. (Presenter), Ofoegbu, A. (Co-Presenter), “Vaccine Hesitancy in the Black Community.”, “Vaccine Hesitancy in the Black Community.”, African Canadian Heritage Association, Online, Toronto, Canada. (January 2021).
- Ettienne, E., University of Maryland Eastern Shore, “Strategies for Research and Teaching During the COVID-19 Pandemic,” University of Maryland Eastern Shore, On-Line. (December 2, 2020).
- Ettienne, E. (Moderator), Howard University Ideas Symposium, “Howard University Ideas Symposium “From Protest to Policy: The Pursuit of Racial Justice”,” Howard University, Online, Washington, DC, United States. (October 14, 2020).
- Sarpong, K. (Presenter), Ofoegbu, A. (Presenter), Ettienne, E. (Researcher/Presenter), Atiase, Y. (Presenter), Amoah, A. (Presenter), ASHP Midyear Meeting 2019, “Comorbid Mood Disorder Assessment in a Ghanaian Cohort of Diabetic Patients,” ASHP, Convention Center, Las Vegas, NV, United States. (December 2019).
- Ettienne, E. B. (Presenter), Boris Lawrence Henson Foundation Conference “Can We Talk”, “Understanding Addiction and the Drug Epidemic,” Boris Lawrence Henson Foundation, Hyatt Washington, Washington, DC, United States. (June 8, 2019).
- Ezeude, G. (Presenter), Briggs, J. (Presenter), Walker, C. (Presenter), Williams, S. (Presenter), Ofoegbu, A. B. (Researcher/Presenter), Ettienne, E. (Researcher/Presenter), ASHP Midyear 2018, “Clinical Pharmacogenomics Testing in Opioid Use Disorder Management: A Retrospective Cohort Study,” ASHP, Convention Center, Anaheim, CA, United States. (December 2018).
- Avalime, D., Weaver, S., Maneno, M., Ettienne, E. (Presenter), American Society of Consultant Pharmacists, “Opioid Use and Screening and Assessment Tool for Older Adults.”, ASCP, National Harbor, Oxon Hill, MD, United States. (November 2, 2018).
- Ettienne, E., AACP Meeting, “Interdisciplinary Approaches to Combating the Opioid Use Disorder Epidemic: Lessons Learned From Howard University,” AACP, AACP Annual Meeting, Boston, MA, United States. (July 2018).
- Wingate, L., Maneno, M., Weaver, S., Habib, M., Karodeh, Y., Ettienne, E., Marcus, M., American Association of Colleges of Pharmacy, “Predictors of High Performance on the NAPLEX at a Historically Black College of Pharmacy,” AACP, Haynes Convention Center, Boston, United States. (July 23, 2018).
- Habib, M., Weaver, S., Wingate, L., Karodeh, Y., Marcus, M., Ettienne, E., Maneno, M., American Association of Colleges of Pharmacy, “Determination of Predictors Impacting Performance on the Pharmacy Curriculum Outcomes Assessment at a Historically Black College of Pharmacy,” AACP, Boston, Boston, MA, United States. (July 22, 2018).
- Ettienne, E., Caribbean Medical Providers Practicing Abroad (CMPPA) Annual Medical Conference, “Debunking the Myth: Generic vs Name Brand Medications”., Caribbean

- Medical Providers Practicing Abroad, Hyatt Regency Hotel, Port of Spain, Trinidad and Tobago. (June 9, 2018).
- Ettienne, E. (Presenter), Opioid Crisis Symposium, Bowie State University, "The Role of the Pharmacist in the Opioid Epidemic," Health Policy Research Consortium/Bowie State University, Bowie State University, Bowie, MD, United States. (May 9, 2018).
- Ettienne, E., Research Week 2018, "Implementing Pharmacogenomics Testing in a Ghanaian Cohort," Howard University, Blackburn center, Washington, DC, United States. (April 2018).
- Ettienne, E. (Presenter), Regulatory Science and Compliance Lecture Series, Addis Ababa University, "Fundamentals of Regulatory Affairs and Policy," USAID/Adis Ababa University, Adis Ababa University, Adis Ababa, Ethiopia. (March 19, 2018).
- Ettienne, E. (Principal Investigator), Ofoegbu, A., Wilson, B., Maneno, M., Briggs, J., Walker, C., Ezeude, G., Chapman, E., National Institute on Drug Abuse (NIDA) Consortium Meeting, "Pharmacogenomics in Opioid Use Disorder Management.," National Institute on Drug Abuse (NIDA), 6001 Executive Blvd. North Bethesda, MD 20892, Bethesda, MD, United States. (January 9, 2018).
- Ettienne, E. (Principal Investigator), Ofoegbu, A., Wilson, B., Sarpong, K., Traore, M., Kayode, B., Philogene, T., Nunlee-Bland, G., Anderson, W., Dunston, G., Research Centers in Minority Institutions (RCMI) Conference, "Pharmacogenomics and Diabetes Management Implications," Research Centers in Minority Institutions, Marriott Washington Wardman Park Hotel., Washington, DC. (October 31, 2017).
- Ettienne, E. (Principal Investigator), Ofoegbu, A., Wilson, B., Sarpong, K., Kayode, B., Maneno, M., Philogene, T., Nunlee-Bland, G., Anderson, W., Dunston, G., Temple University School of Pharmacy (TUSP) American Association of Pharmaceutical Scientists (AAPS) One-Day Symposium, "Pharmacogenomics and Diabetes Management Implications," American Society of Pharmaceutical Scientists, Temple University, Philadelphia, PA, United States. (October 13, 2017).
- Ettienne, E. (Presenter/PI), Ofoegbu, A., Wilson, B., Kayode, B., Maneno, M., Briggs, J., Williams, S., Walker, C., Nguyen, K., Ezeude, G., Chapman, E., Howard University Research Day on Capitol Hill, "Pharmacogenomics in Opioid Use Disorder Management," Howard University, Capitol Hill Rayburn Office Building, Washington. (October 3, 2017).
- Ettienne, E. (Presenter/PI), Southeastern Consortium for Substance Abuse Training. Live Webinar, "Clinical Application of Pharmacogenomic Testing in Opioid Use Disorder Management", " Southeastern Consortium for Substance Abuse Training, On-Line, Washington, DC, United States. (September 29, 2017).
- Ettienne, E., Annual Conference of the African Association of Rhetoric., "Economic Community of West African States' (ECOWAS) Inclusion in the International Council of Harmonization (ICH) Initiative: Overcoming Barriers to Pharmaceutical Global Regulatory Harmonization.," University of Pretoria, Manhattan Hotel Pretoria, Pretoria, PA, South Africa. (July 4, 2017).
- Ettienne, E. (Presenter), National Institutes of Health, Summer Genetics Institute, "Precision Medicine and Pharmacoeconomic Implications on Health Policy", " NIH, NIH Bethesda, Bethesda, MD, United States. (June 16, 2017).
- Ettienne, E. (Presenter), Howard University Research Day, "Clinical Pharmacogenetic Testing in the Management of Opioid Use Disorder (OUD): A Case Series", " Howard University, Blackburn Center, Washington, DC, United States. (April 13, 2017).

Ofoegbu, A. (Presenter), Ettienne, E. (Presenter), Yeboah, A., Sarpong, K., Amoah, A., Sackeyfio, A., Anderson, W., Dunston, G., Howard University Research Day, "Clinical Pharmacogenetic Testing as Clinical Decision Support for Diabetes Management in a Ghanaian Cohort," Howard University, Blackburn Center, Washington, DC. (April 13, 2017).

Ettienne, E., Oishi, T., Ofoegbu, A., Sarpong, K., Maneno, M., Wingate, L., Gyasi, K., Howard University Research Day, "Economic Community of West African States' (ECOWAS) Inclusion in the International Council of Harmonization (ICH) Initiative: Overcoming Barriers to Pharmaceutical Global Regulatory Harmonization," Howard University, Blackburn Center, Washington, DC, United States. (April 13, 2017).

Ettienne, E. (Presenter), RCMI Team Science Symposium, "Starting and Managing Industry Partnerships", RCMI, Research Building Howard University, Washington, DC. (April 12, 2017).

Ettienne, E. (Presenter), National Medical Association Regional Conference, National Harbor MD, "Clinical Pharmacogenomics Testing as a Path to Value-Based Health Care", National Medical Association, Gaylord, Washington, DC, United States. (April 11, 2017).

Ettienne, E. (Presenter), Ofoegbu, A. (Presenter), Dunston, G., Anderson, W., Sackeyfio, A., Rosenblatt, K., Amoah, A., American Pharmacist Association Meeting in San Francisco CA, (64), "The Predictive Value of Pharmacogenomic Testing on Diabetes Treatment Outcomes in a Ghanaian Cohort," American Pharmacists Association, San Francisco Convention Center, San Francisco, CA, United States. (March 25, 2017).

Ettienne, E. (Presenter), National Health IT Collaborative for the Underserved Conference, National Harbor MD, "Creating Economic Opportunities through Genomics and Precision Medicine", Premier DNA, National Harbor MD, Washington, DC, United States. (December 14, 2016).

Legrand, M., Ofoegbu, A. (Presenter), Nunlee-Bland, G. (Presenter), Ettienne, E. (Presenter), American Society of Health-Systems Pharmacists(ASHP) Midyear Conference, "Pharmacogenomics and Diabetes: The Relationship Between Mood Disorders and Treatment Outcomes.," Howard University, Blackburn Center, Las Vegas, United States. (December 6, 2016).

Ettienne, E. (Discussant), Academy Health Concordia, "Meaningful Use: Developing Computer Algorithms to Identify Potential Adverse Events from Electronic Medical Record Data", Academy Health, Hilton Alexandria, Alexandria, VA, United States. (September 19, 2016).

Ettienne, E. (Presenter), African Association of Rhetoric conference Windhoek, Namibia, "Public Choice and Rhetoric: Advancing Genomic Medicine through Health Policy", African Association of Rhetoric, Protea Hotel Windhoek, Windhoek, Namibia. (July 5, 2016).

Ettienne, E. (Presenter), Howard University College of Medicine Retreat, Association of American Medical Colleges, Washington DC, "The Journey: Teaching Well", College of Medicine, Association of Medical Colleges, Washington, DC, United States. (May 26, 2016).

Carson, R., Ofoegbu, A., Uwe, S., Asamoah-Darko, F., Ettienne, E., Dunston, G., Amoah, A., Anderson, W., Howard University Research Week, Washington, D.C. (153), "Comorbid Depression in Diabetes: A Comparative Study of Prevalence Between the United States and a Ghanaian Cohort," Howard University, Blackburn Center, Washington, DC, United States. (April 14, 2016).

Major, J., Ettienne, E., Maneno, M., Wingate, L., Howard University Research Week, Washington, D.C. (47-48), "Examining the Role of Historically Black Colleges and Universities (HBCUs) in Promoting Diversity in the Pharmacy Workforce." (April 14, 2016).

Ettienne, E., Ofoegbu, A., Weaver, S., Akiyode, O., Wingate, L., Maneno, M., Nunlee-Bland, G., Dunston, G., Amoah, A., Anderson, W., Advancing Computational Biology at Howard University Symposium, Washington, D.C. (12), "Pharmacogenomics and Protein: The Pharmacodynamics of Antidiabetic Medications.," RCMI, Gallaudet University, Washington, DC, United States. (April 8, 2016).

Ettienne, E. (Presenter), Office of Regulatory Research Compliance, Lecture Series, Howard University, "The HIPAA Privacy Rule, Institutional Review Boards and the Research Process", Office of Regulatory Research Compliance, Health Sciences Library, Washington, DC, United States. (April 6, 2016).

Ettienne, E. (Researcher/Presenter), Nunlee-Bland, G. (Presenter), Dunston, G. (Presenter), Ofoegbu, A. (Presenter), Howard University Research Week, Washington, D.C. (171), "Pharmacogenomics as Clinical Decision Support in Comorbid Depression in Diabetes," Howard University, Blackburn Auditorium, Washington, DC, United States. (April 16, 2015).

Ettienne, E. (Researcher/Presenter), Dunston, G., Ofoegbu, A., National Institute on Minority Health and Health Disparities (NIMHD) Fall Conference, "Pharmacogenomic Implications and the Treatment of Asthma: A Comparison between Accra, Ghana and Washington DC," NIH, Gaylord Hotel and Convention Center, Oxon Hill, MD, United States. (December 1, 2014).

Ettienne, E. (Researcher/Presenter), Ofoegbu, A. (Presenter), Dunston, G. (Presenter), Annual Conference of the International Educators Group/International Academy of Business, "Pharmaceutical Care Coordination and Genomics in Emerging Markets: A Business Case for Ghana," International Educators Group, Crystal City Courtyard Marriott, Arlington, VA, United States. (November 22, 2014).

Ettienne, E. (Researcher/Presenter), Ofoegbu, A. (Presenter), Howard University Research Day Washington D.C. (146-47), "Clinical Decision Support and Pharmacogenomic Testing in Ethnically Diverse Major Depressive Disorder Patients," Howard University, Blackburn Center, Washington, DC. (April 4, 2014).

Ettienne, E. (Presenter), Maryland Legislature Disparities Conference, Annapolis MD, "The Transatlantic Slave Trade, Global Health and Health Disparities: Pharmacogenomics One Way Forward", Maryland Legislature, State House Maryland, Annapolis, MD, United States. (November 15, 2012).

## **Contracts, Fellowships, Grants and Sponsored Research**

Ettienne, E. (Principal), Weaver, S. (Supporting), "GlaxoSmithKline/Howard University Regulatory Affairs Fellowship," Sponsored by GSK Pharmaceuticals, Private, \$1,335,000.00. (July 2022 - June 2027).

Awuonda, M. (Principal), Wingate, L., Turner, M., Franklin, C.-J., Akala, E., Mims, B., Akiyode, O., Unonu, J., Drame, I., Kulkarni, A., Mckoy, Y., Weaver, S., Ettienne, E., Daftary, M., Adesina, S., Rungkitwattanukul, D., Hailemeskel, B., McCants, T., Jorden, J., "Howard University Center of Excellence," Sponsored by HRSA, Federal, \$3,430,000.00. (July 1, 2022 - June 30, 2027).

Ettienne, E. (Principal), "Howard/Sanofi Postdoctoral Fellowship," Sponsored by Sanofi Pharmaceuticals, Private, \$8,269,760.00. (July 1, 2022 - June 30, 2027).

Ettienne, E. (Principal), "Amgen Doctoral Fellowship- Global Regulatory Affairs & Medical Affairs," Sponsored by Amgen Pharmaceuticals, Private, \$2,712,200.00. (June 2022 - June 2027).

Ettienne, E. (Principal), "AstraZeneca Fellowship Development in Medical Affairs/Oncology/Respiratory," Sponsored by Astra Zeneca, Private, \$1,512,200.00. (July 1, 2021 - June 30, 2027).

Ettienne, E., "Genentech Fellowship Renewed and Expanded," Sponsored by Genentech Pharmaceuticals, Private, \$3,123,960.00. (July 1, 2020 - June 30, 2027).

Ettienne, E. (Principal), "GlaxoSmithKline/Howard University Medical Affairs Fellowship Renewed," Sponsored by GSK Pharmaceuticals, Private, \$3,739,780.00. (July 1, 2018 - June 30, 2027).

Ettienne, E. (Principal), "Pfizer Regulatory Affairs- labeling Fellowship," Sponsored by Pfizer, Private, \$412,000.00. (March 2016 - June 30, 2027).

Ettienne, E., "Actelion/Jansen fellowship Grant," Sponsored by Actelion/Jansen fellowship Grant, Private, \$256,550.00. (July 1, 2024 - June 30, 2026).

Ettienne, E., "Merck Fellowship," Sponsored by Merck, Private, \$243,600.00. (July 1, 2024 - June 30, 2026).

Ettienne, E., "Bayer Fellowship Grant," Sponsored by Bayer Pharmaceuticals, Private, \$240,000.00. (July 1, 2024 - June 30, 2026).

Ettienne, E., "United Therapeutics Fellowship Grant," Sponsored by United Therapeutics, Private, \$243,600.00. (July 1, 2024 - June 30, 2026).

Ettienne, E., "Reagan Udall Fellowship Grant," Sponsored by Reagan Udall Foundation, Federal, \$40,000.00. (July 2023 - June 2026).

Ettienne, E., "BioMarin Fellowship Grant Renewed," Sponsored by BioMarin Pharmaceuticals, Private, \$456,000.00. (July 1, 2022 - June 30, 2026).

Ettienne, E. (Principal), "AbbVie Fellowship Development in Medical Affairs and Medical Information," Sponsored by AbbVie Pharmaceuticals, Private, \$1,260,500.00. (July 1, 2022 - June 30, 2026).

Ettienne, E. (Principal), "Jansen Fellowship Development in Medical Information/Medical Affairs/Real-World Value and Evidence," Sponsored by Janssen, Private, \$966,209.00. (July 1, 2022 - June 30, 2026).

Ofoegbu, A. (Principal), Ettienne, E. (Co-Principal), "2024-2025 Faculty Research Initiative Grant," Sponsored by Thurgood Marshall College Fund (TMCF) and Novartis US Foundation, Private, \$25,000.00. (June 1, 2024 - September 30, 2025).

Awuonda, M. (Principal), Ettienne, E. (Co-Principal), "The Public Health Informatics & Technology (PHIT) Workforce Development Program -- PHIT4DC," Sponsored by UDC, State, \$3,432,670.00. (September 2021 - September 20, 2025).

Ettienne, E. (Principal), Wutoh, A. (Co-Principal), "Lilly USA Courseware Grant on Drug Development Course," Sponsored by Lilly USA, Private, \$50,000.00. (June 4, 2020 - June 2025).

Ettienne, E. (Principal), "Designing and Implementing a Regulatory Affairs Fellowship," Sponsored by Pfizer, Private, \$672,333.00. (February 2018 - June 2025).

Weaver, S., Ettienne, E., Taylor, J., Wingate, L., Diaz, S., "RCMI Investigator Development Core (IDC) Grant," Sponsored by Howard University Research Centers in Minority Institutions (RCMI) through NIMHD/NIH, Federal, \$96,562.00. (April 30, 2024).

Wutoh, A. (Principal), Awuonda, M. (Co-Principal), Wingate, L. (Supporting), Ettienne, E. (Supporting), Tofade, O. (Co-Principal), "National Workforce Diversity Pipeline Program," Sponsored by HHS Office of Minority Health, Federal, \$2,500,000.00. (July 1, 2015 - June 30, 2020).

Anderson, W. (Principal), Eribo, B. (Co-Principal), Dunston, G. (Co-Principal), Wutoh, A., Morris, V. (Co-Principal), Manaye, K. (Co-Principal), Akala, E. (Supporting), Bakare, O. (Supporting), Kassim, K. (Co-Principal), Macias, C. (Supporting), Gugsa, A. (Supporting), Ettienne, E., "Minority Health and Health Disparities International Research Training," Sponsored by NIMHD, Federal, \$1,285,000.00. (July 2014 - June 2020).

Ettienne, E. (Principal), "Medication-Assisted Treatment Genomic Registry," Sponsored by DC Healthcare Finance, State, \$250,000.00. (June 4, 2018 - September 4, 2018).

## Exhibits and Performances

Ettienne, E., "HBCU Are Essential to Improving Diversity in Pharmacy," Pharmacy Times, Internet Video. (February 2023).

Ettienne, E., Tofade, T., Ofoegbu, A., Washington, L., "Interdisciplinary Policy Symposium," Anthony Wutoh PhD, RPh Provost, Washington, DC, United States. (November 2, 2017).

## Research Activity

"Pharmacogenomics and Pediatric Drug Development" (On-Going). (June 20, 2024 - Present).  
Pharmacogenomics (PGx) investigates how genomes control enzyme expression.  
Developmental pharmacology (DP) describes the temporal sequence of enzymes impacting absorption, distribution, metabolism, and excretion (ADME) of food and drugs.  
Areas covered US and European Union (EU) legislation facilitate and/or enforce pediatric studies for all new drugs, called overall 'pediatric drug development' (PDD). DP and PDD look at patients' chronological age, but oscillate between legal and physiological meanings of the term 'child.' Children's bodies become mature with puberty.  
Expert opinion Decades after first DP observations in babies, PGx offers a better understanding of the variability of safety and efficacy of drugs, of the process of aging, and of shifting enzyme patterns across aging. We should rethink and revise outdated interpretations of ADME changes in minors. The Declaration of Helsinki forbids pointless studies that some pediatric researchers and regulatory agencies, more so the EMA than the FDA, demand pointless pediatric studies is regrettable. Medicine needs to differentiate between legal and physiological meanings of the term 'child' and should use objective measures of maturity.

"Regulatory Strategies for Accelerating DNA, ALVAC-HIV, and gp120 IND" (On-Going). (February 12, 2023 - Present).  
Preclinical research conducted at the Animal Models Retroviral Vaccine Section (AMRVS) of the National Cancer Institute (NCI) contributed to the development of the recombinant ALVAC-HIV prime-gp120/Alum boost regimen tested in the RV144 Trial. The risk of HIV-1 acquisition was reduced by 31.2% following a modified intention-to-treat analysis up to 42 months in the RV144 Trial. In the last decade, the AMRVS built and validated a robust

macaque model that recapitulated the positive results of RV144 and used it to improve relative vaccine efficacy. This macaque model was developed by mucosal exposure of Indian Rhesus macaques to the neutralization-resistant Simian Immunodeficiency Virus (SIVmac251) propagated in macaque PBMCs, mimicking the natural exposure during human HIV infection. Following the performance of over 12 preclinical studies that included recombinant ALVAC, performed using SIV or SHIV challenge viruses, the AMRVS plans to conduct a Phase 1 HIV-1 preventative trial in healthy adults at two clinical sites in the United States. The newly developed regimen includes priming with DNA plasmids (cDNAs) encoding Virus Particles (VLP) followed by a live canarypox virus (ALVAC-HIV), also encoding VLP, and one adjuvanted envelope glycoprotein boost. More recently, this vaccine regimen, combined with topical administration of a zing finger inhibitor, SAMT-247, significantly improved vaccine efficacy in female macaques. Clinical testing of first-in-human vaccines in the United States is subjected to Food and Drug Administration (FDA) concurrence under the Investigation New Drug Application (IND) process. I plan to develop a novel regulatory approach to expedite this new regimen to the clinic.

"Howard University Genomics- Enhanced Medication - Assisted Treatment (HUGE-MAT) Registry Project" (On-Going). (September 15, 2018 - Present).

The mission of the HUGE-MAT Registry is to improve the treatment landscape of opioid use disorder (OUD) via the generation of evidence guiding the use of genomics to improve the provision of medication-assisted treatment (MAT). The vision of the HUGE-MAT Registry is to serve as a central location for the submission of genetic test information that healthcare providers can use to augment the clinical decision-making process for the induction, stabilization, and maintenance of MAT based OUD management. We value the lives of those that are impacted by opioid use disorder, including patients, families, and communities, and we encourage the use of real-world evidence to augment the care provided by clinicians and to facilitate future research opportunities and health policy recommendations.

"Pharmacogenomic decision making pathway in the optimal management of opioids in patients with sickle cell disease" (Writing Results). (November 2, 2021 - November 1, 2025).

Research Goal: The goal of the research project is to identify genetic polymorphisms associated with response to pain and opioid medications in patients with SCD.

Proposed Objectives

Aim 1: To detect the frequencies of the polymorphisms of the genes 3A4, 2D6, 2C19, 2C9, COMT and drug gene interactions in patients with SCD.

Aim 2: To evaluate the number of recommendations made for patient based on actionable genotypes found at baseline, 6 months and 12 months.

Aim 3: To assess the quality of life of patients before and after the change in their pain medication regimen using pharmacogenomic data at baseline, 6 months and 12 months.

"Discoverability of Scientific Information: Assessing Google Indexing of Scientific Content Among Pharmaceutical Companies" (Complete). (February 3, 2025 - June 30, 2025).

The purpose of this study is to investigate how pharmaceutical companies index their medical/scientific content on search engines, particularly google. We seek to understand the current practices, challenges and strategies used in optimizing medical/scientific contents for better visibility and accessibility. There is an opportunity to improve the general access to quality medical/scientific information using these search engines.

"phactMI Benchmarking Survey on Content Development and Key Performance Indicators" (Complete). (April 23, 2024 - June 2025).

Medical information (MI) departments across pharmaceutical companies strive to offer timely, accurate, and scientifically balanced responses about a company's products to healthcare professionals (HCPs), payors, patients, and caregivers. Content development in MI is pivotal in the pharmaceutical industry as it ensures that responses to medical inquiries are relevant, accurate, and scientifically balanced. Appropriately developed content enhances

communication with HCPs, payors, patients, and caregivers. Key performance indicators (KPIs) play a crucial role in evaluating content development effectiveness, providing measurable insights, and impact of medical information departments. Monitoring KPIs enables pharmaceutical companies to optimize processes, enhance customer satisfaction, and stay abreast with current trends. Past benchmarking surveys of MI groups have been conducted to assess current trends to identify areas of optimization that ultimately benefit the customers. This research investigates to understand the current trends in content development and key performance indicators (KPIs), comparing the trends with the 2018 Pharma Collaboration for Transparent Medical Information (phactMI) benchmark study.

"Assessing Factors Impacting African American Participation in Pediatric Type II Diabetes Clinical Trials Perspectives" (Complete). (June 8, 2017 - May 8, 2020).

**Background:** The prevalence of Pediatric Type 2 Diabetes Mellitus (PT2DM) is a global concern. This rise goes concurrently with the obesity epidemic in youth and the ethnic minorities are mainly affected. As such, there is an urgent need for successful clinical trials to increase the knowledge on management, disease progression and optimal treatment choices. The available medications for PT2DM are not meeting the needs.

**Objective:** The objective of the study was to evaluate the factors impacting African American participation in pediatric Type 2 diabetes mellitus clinical trials (PT2DMCT) while evaluating insights from key stakeholders—Caregivers, Providers, and Regulators.

**Methods:** We employed a three-arm mixed-method study design utilizing focus groups and surveys of caregivers and providers and key informant interviews of regulators. The primary outcome of the study was to evaluate factors that impact Caregivers' and Providers' intention to enroll or refer their children and/or patients (less than 18 years of age) to PT2DMCT. The secondary objective was to explore the attitude, subjective norm, perceived behavioral control and emotions of Caregivers and Providers surrounding their intention to enroll their children and/or patients to PT2DMCT. A modified survey tool derived from Ajzen's, Theory of Planned behavior was used to measure perceived behavioral control, subjective norm, attitude and intention. Emotion was measured using the Positive Affect and Negative Affect Schedule (PANAS), and the trustworthiness of the qualitative content of the providers, caregivers and regulators was assessed using Lincoln and Guba's Qualitative Content Analysis. Survey data was collected using Qualtrics, interviews and focus groups were conducted using 20|20 Research's QualMeeting@webcam interview platform. Key informant interviews were conducted through audio recorded phone calls. The focus groups and interviews were assessed using Braun and Clarke's thematic analysis. Caregivers and providers in this study had to be adults greater than 18 years of age and reside in the US. Key informants had to be over the age of 18 and have direct working regulatory knowledge of clinical trials. Logistic regression was used to analyze the data and inform the results for the surveys. The key informant interviews sought to elicit perspectives surrounding barriers, positive aspects, negative aspects, emotions, recommendations and expertise regarding pediatric clinical trials. The interviews were aggregated, thematically analyzed and used to draw conclusion surrounding the overall outlook of PT2DMCT.

**Results:** One hundred and eight (108) Caregivers of African American children with T2DM living in United States were surveyed. The mean age of the participants was 39 years and 53.4% were females. The findings from the multivariate analysis showed that work hours per week (p-value = 0.001), total attitude score (p-value = 0.032), total positive affect score (p-value = 0.029) and total perceived behavioral control score (p-value = 0.002) were the only statistically significant predictors of "intention to enroll their child", adjusting for other variables.

Ninety-two (92) T2DM Providers were surveyed. The mean age of the Providers was 39.75, a little over half were females (59.8%) and majority of them were Caucasians (45.7%). Physicians accounted for 60.8% and when asked if they refer patients to clinical trials, 69.6% stated yes. The findings from the multivariate analysis showed that total attitude score (p-value = 0.011), total positive affect score (p-value = 0.041) and total subjective norm score (p-value = 0.044) were the only statistically significant adjusted predictors of "intention to refer

their patient.”

The focus groups revealed that Provider and Caregiver focus groups saw clinical trials as an idea of hope and emotions are sentiments that drive their decisions. Providers further mentioned, reasons for them to refer patients to CTs and their built-in relationships with the patients as essential factors when referring them to clinical trials. Caregivers stated that the impact of the disease on their lives as life-changing and burdensome, and trial logistics and compensations need to be feasible when it comes to enrollment decisions for their child. Regulators key informant interviews concluded five themes positive aspects, negative aspects, PDCTs not meeting the needs, recommendations and impact of emotions regarding pediatric CTs.

Conclusion: The study confirmed factors such as attitude, subjective norm and positive affect were significant predictors for the intention of Providers to refer their patients to PT2DMCTs adjusting for all other variables. For the Caregivers’ intention to enroll their child to a PT2DMCT work hours per week, perceived behavioral control, attitude and positive affect were significant predictors after adjusting for all other variables. These factors need to be taken into account when designing PT2DMCTs. The qualitative themes revealed from the focus group of Caregivers and Providers and Key Informant interview with regulators were consistent with existing literatures. This study provides novel insights into the perspectives of the different key stakeholder’s’ intentions regarding clinical trial enrollment, referrals, designs, and implementation, and it underscores that “emotions” are important considerations.

"Pharmacogenomics and Diabetes: The Relationship between Mood Disorders and Treatment Outcomes" (Complete). (May 5, 2016 - March 30, 2020).

The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Diabetes prevalence has been rising more rapidly in middle- and low-income countries [1]. Research suggests that comorbid diabetes and depression is common; however, the implications for clinical practice remain unclear [2]. Depression increases the risk of the development of type 2 diabetes mellitus (T2DM) and the subsequent risks of hyperglycemia, insulin resistance, and micro- and macrovascular complications. Conversely, a diagnosis of T2DM increases the risk of incident depression and can contribute to a more severe course of depression [3]. Specifically, in Ghana, studies in the general population have estimated that between 3.3 and 6% of the population has diabetes with the prevalence increasing with age and being higher in urban than in rural areas [4].

OBJECTIVES The objective of this research is to determine if there is a correlation between diabetes and mood disorder in our cohort of diabetes patients at the Korle Bu Teaching Hospital in Accra, Ghana

"Retrospective Cohort Study of Clinical Pharmacogenetic Testing in the Management of Opioid User Disorders" (On-Going). (September 8, 2017 - August 30, 2018).

The purpose of this study is to determine the impact of pharmacogenetic-guided buprenorphine dosing on OUD management outcomes, specifically as it pertains to relapses to unauthorized substances. The expected benefits of this study are that pharmacogenetic testing will help to guide the clinician to buprenorphine dosing that will minimize or eliminate relapse to unauthorized substances and reduce or eliminate withdrawal symptoms. Ultimately, improving OUD management may result in improved overall health, improved productivity, reduced criminal activity, reduced risk of contracting a human immunodeficiency virus (HIV) or hepatitis C (HCV) infection, and reduced risk of death.

"Development of a Pharmacy Star Rating System & Education of Community Pharmacists on Star Rating and Pay" (Complete). (April 21, 2015 - May 21, 2016).

Objective and Key Research Questions

There are 2 primary objectives for this project.

Objective 1: Create an overall "Pharmacy Star Rating" system that could be used to inform the public about the quality of community pharmacies. Our research will answer the following questions to guide the development of this rating system:

1. How can the individual quality measures from PQA be used to calculate an overall Star Rating for a pharmacy?
2. Using the EQuIPP dataset, how many pharmacies would achieve a 1,2,3,4,5-star overall rating based on the draft model?
3. How much does a pharmacy's Star Rating vary across Part D plans? If there is wide variation in pharmacy performance across plans, how do we account for any factors that influence this variation?
4. What are the opinions of key stakeholders on the Pharmacy Star Rating model? How do these opinions vary between independent pharmacy owners, chain pharmacy executives, and managed care executives?
5. What feedback do consumers have on the Pharmacy Star Rating model?

Objective 2: Prepare and distribute educational programs for community pharmacists related to Medicare Star Ratings, quality improvement and new payment models that will be coupled with quality metrics (e.g., Pay-for-Performance [P4P]).

"The Power of the Electronic Medical Record (EMR) in the 21st Century Era of Precision Medicine" (Complete). (March 30, 2015 - April 1, 2016).

Depression and diabetes are non-communicable diseases that carry an enormous public health burden. The presence of depression in diabetics increases the difficulty of managing the diabetes and leads to an increased likelihood of reported diabetic symptoms, more office visits, more same-day appointments, more missed visits, and a higher mortality rate (Jansen Ph D 2014). Though the causal relationships have not been elucidated, comorbid depression in type 2 diabetes is strongly associated with increased mortality (Wayne J Katon 2005). The electronic medical record (EMR) is a powerful tool that can be used to gain a deeper understanding of trends in patient characteristics and improve resource allocation. This research seeks to achieve the following specific aims:

Specific Aim 1. Employ the electronic medical record (EMR) to determine the correlation between PHQ-9 scores and HbA1C levels. We will achieve this by entering the PHQ-9 scores and HbA1C levels into IBM SPSS statistical software and conducting a Pearson correlation test.

Specific Aim 2. Identify the outlier patients and determine if outliers are instructive of any particular trends. We will approach this by conducting univariate analysis of the PHQ-9 scores and HbA1C levels to determine the averages and standard deviations. Patients that fall outside of two standard deviations above (outside) the average would be characterized and observed.

Specific Aim 3. Conduct a longitudinal analysis of individual patient PHQ-9 scores and HbA1C levels to determine specific trends in the data. We will employ IBM SPSS statistics to run a Pearson correlation test on each individual patient's PHQ-9 score and HbA1C level from their first visit to the clinic to their most recent visit to the clinic and determine if any trends warrant further analyses.

Specific Aim 4. Conduct a pharmaco-economic analysis comparing the cost associated with treating non-depressed diabetic patients compared to patients with comorbid depression in diabetes. We will employ a Cost of Illness (COI) where we will estimate the magnitude of resources needed to treat diabetics with and without depression. The analysis employs direct and indirect costs associated with prevention, treatment and disease-related morbidity and mortality. This will provide insight into the value of treating or preventing diabetes and or depression. In summary, our aim is to use the EMR to determine characteristics unique to the patient population of the Diabetes Treatment Center and determine the costs associated with

diabetes as compared to comorbid depression in diabetes. In future research, we would like to determine the underlying biological mechanisms that lead to the unique characteristics present in the outlier patient population and determine whether the use of clinical decision support using pharmacogenomics is cost effective and or beneficial.

"Pharmacogenomics Education & Engagement for Multicultural Care Coordination" (Complete). (September 20, 2013 - August 30, 2014).

The Joint Center for Economic and Political Studies reported that between 2003 and 2006 an estimated 30.6% of direct medical care expenditures for African Americans, Asian Americans, and Hispanics were excess costs caused by health inequalities. The same study also showed that the combined costs of health inequalities and premature deaths in the same period rose to 1.24 trillion dollars. Incorporating more targeted pharmacogenomics interventions could potentially save the health system billions of dollars and improve health outcomes

Primary study endpoint: GeneSightRx® will predict antidepressant response in minority patients but at a much lower % than currently seen in the majority population.

#### Objectives

1. Test the hypothesis that the algorithm employed in the GeneSightRx® pharmacogenomics test has applicability in ethnically diverse Major Depressive Disorder patients
2. Conduct a Pharmacoeconomic analysis of the GeneSightRx® algorithm as a pretreatment criteria for drug selection

"Cost-Effectiveness Analysis of two Antiretroviral Therapies for Children with HIV in Resource-Constrained Areas with Peripartum Nevirapine Exposure from the Perspective of Payers" (Complete). (November 4, 2013 - April 30, 2014).

BACKGROUND: Due to the high disease burden in children HIV in Africa, a regimen including nevirapine (NVP) is often the predominant antiretroviral therapy (ART) available for HIV-infected children because of its relatively lower cost, better stability profile at high temperature, and convenience of the availability in a fixed dose combination. Despite the benefits of NVP, challenges exist from the effect of NVP resistance in mothers as well as in children who become infected with HIV regardless of prophylaxis. As a result of these concerns, ritonavir-boosted lopinavir (LPV/r) based regimens which are more expensive are preferred over the less costly NVP based regimens.

STUDY OBJECTIVE: To evaluate the cost-effectiveness of LPV/r based regimen as either the first line therapy or an induction therapy based on a cost effective analysis between 3TC+ABC + LPV/r regimen vs. 3TC +ABC+ NVP regimen from the perspective of payers. METHODS: Clinical data were collected from published studies of antiretroviral treatment for children in Africa. The following costs were calculated: costs related to ARV drugs, costs of the laboratory test, costs of the diagnostic test, and costs of hospitalization. Markov Models were designed for LPV/r-based regimen and NVP- based regimen with three HIV transition states including chronic HIV infection, acute clinical events, and death. The model calculated the incremental cost-effectiveness ratios (ICERs) from payer's perspective in 2013 US dollars with QALYs as an outcome. To evaluate the variability of input data on the final results of the study, sensitivity analyses were conducted to examine the impact of varying base case assumptions on the costs, discount rate, and differences in survivability.

RESULTS: In all models conducted, the findings of the ICERs based on mean costs and mean effectiveness showed that treating strategies consisting of NVP-based regimen dominated the LPV/r-based regimen with the ICERs that range from -\$100,986.95/QALY to -\$392.30/QALY.

The result also revealed an estimated 0.79 years gained in Life expectancy from LPV/r treatment regimen over NVP treatment regimen. Direct medical costs and effects of rates of virologic failure or mortality rates are the major variables that influence the outcome of this study. The lesson to be learned from this study is that in treating HIV infected children in

South Africa, the NVP-based regimen would lead to cost savings, but at the same time to loss of effectiveness.

## Teaching Experience

CLPS 312, Principles of Pharm Admin, 4 courses.  
CLPS 318, - Pharmacy Pharm Law & Policy, 6 courses.  
CLPS 340, Pharm Jurisprudence, 8 courses.  
CLPS 428, Principles of Pharmacy Administration I, 7 courses.  
CLPS 452, - Pharmacy Principles of Pharm Admin 2, 6 courses.  
NTDP 626, Principle of Pharm Admin, 3 courses.  
PHSC 319, Making Medicines, 5 courses.  
PHSC 390, Research Rotation, 6 courses.  
PHSC 401, Research Rotation, 23 courses.  
PHSC 405, Research, 8 courses.  
PHSC 418, Pharmacy Law and Policy, 1 course.  
PHSC 535, Pharm Economics I, 1 course.  
PHSC 536, Pharmacy Care Management, 9 courses.  
PHSC 606, Regulatory Writing, 3 courses.  
PHSC 801, Dissertation, 13 courses.  
PHSC 802, Dissertation, 9 courses.  
PHSC 803, Dissertation, 1 course.

## Directed Student Learning

Dissertation Defense Committee Chair, "Women and the Opioid Epidemic: Examining Misuse, Overdose, and Mortality with Related Impacts of Race, Income, and COVID-19." (August 2017 - May 2023).

Advised: Debbynie Barsh

Major advisor for doctoral dissertation, "An Evaluation of the Treatment Outcomes and Policy Implications of Clinical Pharmacogenomics Testing as a Clinical Decision-Making Tool for Opioid Use Disorder Patients." (September 2016 - May 2023).

Advised: Adaku Ofoegbu

Dissertation Committee Chair, "'An Assessment of Telehealth Patient Targets from HCV-HIV hospitalizations and an Evaluation of the Post-Pandemic Acceptability of Pharmacist-delivered Telehealth Services among HCV-HIV patients in Washington DC'." (August 2015 - May 2021).

Advised: Rachel Mayaka

Dissertation Committee Member, "'Formulation and Characterization of Dual Drug-loaded Liposomes for Treatment of Pancreatic Cancer'." (August 2014 - May 2021).

Advised: Shantanu Pande

Major advisor for doctoral dissertation, "'Assessing Factors Impacting African-American Participation in Pediatric Type II Diabetes Clinical Trials: Perspectives from Caregivers, Providers, and Regulators'." (August 2014 - December 2020).

Advised: Tanjinatus Oishi

Dissertation Committee Member, "'Healthcare Resources Utilization, Inpatient Mortality, and Risk Behaviors Among Patients Infected with Hepatitis C Virus in the United States in the Era of Direct-Acting Antivirals'." (August 2014 - April 2020).

Advised: Mohammed Alzarani

Dissertation Committee Member, "Translation and Validation of a Simplified Medication Adherence Questionnaire and Factors Affecting Chronic Diseases Medication Adherence Among Arab Americans". (April 2014 - April 2020).  
Advised: Noor Saeed

Dissertation Committee Member, "Investigating Trends in The Adoption of CPOE System for Medication Orders and Determining Factors Associated with Meeting "Meaningful Use" Criteria for Health IT". (August 2014 - April 2019).  
Advised: Mohammed Malhani

Dissertation Committee Member, "A Web-Based Video Intervention to Increase Knowledge of Medication Safety in Pregnancy and Lactation among Women of Reproductive Age and an Assessment of Knowledge and Application of the new Pregnancy and Lactation Labeling Rule among Pharmacists and Physicians". (January 2014 - June 2018).  
Advised: Ghada Alem

Dissertation Committee Member, "A Web-Based Video Intervention to Increase Knowledge of Medication Safety in Pregnancy and Lactation among Women of Reproductive Age and an Assessment of Knowledge and Application of the new Pregnancy and Lactation Labeling Rule among Pharmacists and Physicians". (September 2012 - April 2017).  
Advised: Raniya Al-Matari

Doctoral Advisory Committee Member, "Synthesis and Characterization of Low Molecular Weight Liquid Crystalline Nanoparticles Designed for Delivery of Drug." (February 2015 - April 2016).  
Advised: Frank Ohwoavworhua

Dissertation Committee Member, "Determinants of HCV Knowledge, HCV Testing Intentions and HCV Treatment Perceptions among African American Baby Boomers" by Mohamed E. Rashrash." (August 2013 - April 2015).  
Advised: Mohamed Rashrash

Major advisor for doctoral dissertation, "Cost-Effectiveness Analysis of Nevirapine vs. Ritonavir-Boosted Lopinavir in HIV-infected Children with Peripartum Nevirapine Exposure in Resource-Constrained Areas from Payer's Perspective" by Onyeka P. Godwin." (August 2012 - May 2014).  
Advised: Onyeka Godwin

## **Mentoring**

Diamond Scott (Fellow). Approx. 50 hours. May 2023 - Present.

Glenn Lyons (Fellow). Approx. 20 hours. June 2022 - Present.

Christopher Punch (Fellow). Approx. 40 hours. 2021 - Present.

Katherine Williams (Fellow). Approx. 80 hours. 2020 - Present.

Olugbenga Awoutunde (Fellow). Approx. 30 hours. 2020 - Present.

Rukiya Umoja (Fellow). Approx. 30 hours. 2020 - Present.

Patrick Fotso (Fellow). Approx. 60 hours. August 2019 - Present.

Alex Johnson (Fellow). Approx. 30 hours. 2019 - Present.

Ashley Dike (Fellow). Approx. 35 hours. 2019 - Present.

Salome Weaver (Faculty Member). Approx. 30 hours. 2019 - Present.

Adaku Ofoegbu (Graduate Student). Approx. 80 hours. 2014 - Present.

Adaeze Anthony-Wise (Fellow). Approx. 15 hours. July 2023 - June 2025.

Abby Obokpolor (Fellow). Approx. 10 hours. June 2023 - June 2025.

Adefemi Ige (Fellow). Approx. 60 hours. June 2023 - June 2025.

Amina Naantaanbuu-Jones (Fellow). Approx. 10 hours. June 2023 - June 2025.

Cynthia Sadera (Fellow). Approx. 10 hours. June 2023 - June 2025.

Deep Patel (Fellow). Approx. 10 hours. June 2023 - June 2025.

Dorothy Agyamang (Fellow). Approx. 10 hours. June 2023 - June 2025.

Emmanuel Opong (Fellow). Approx. 20 hours. June 2023 - June 2025.

Eric Tao (Fellow). Approx. 10 hours. June 2023 - June 2025.

Esteban Fallas (Fellow). Approx. 10 hours. June 2023 - June 2025.

Jennifer Nwosu (Fellow). Approx. 10 hours. June 2023 - June 2025.

Julia Garza (Fellow). Approx. 40 hours. June 2023 - June 2025.

Kennedy Singleton (Fellow). Approx. 10 hours. June 2023 - June 2025.

Kingsley Aguebor (Fellow). Approx. 20 hours. June 2023 - June 2025.

Mustafa Qasim (Fellow). Approx. 10 hours. June 2023 - June 2025.

Natasha Edwards (Fellow). Approx. 40 hours. June 2023 - June 2025.

Philip Matthew (Fellow). Approx. 40 hours. June 2023 - June 2025.

Resacia Degraffeniedit (Fellow). Approx. 10 hours. June 2023 - June 2025.

Rita Ogbonna (Fellow). Approx. 10 hours. June 2023 - June 2025.

Steffan Varghese (Fellow). Approx. 10 hours. June 2023 - June 2025.

Sunwoo Bae (Fellow). Approx. 10 hours. June 2023 - June 2025.

Tyler Sanders (Fellow). Approx. 10 hours. June 2023 - June 2025.

William Namposo (Fellow). Approx. 10 hours. June 2023 - June 2025.

felix Yang (Fellow). Approx. 10 hours. May 2023 - June 2025.

Hadijat Bhadimus (Fellow). Approx. 10 hours. May 2023 - June 2025.

Joseph Gabriel (Fellow). Approx. 5 hours. May 2023 - June 2025.

Kafi Friday (Fellow). Approx. 60 hours. November 2022 - June 2025.

Oluawanifemi Owoseni (Graduate Student). Approx. 20 hours. June 2022 - June 2025.

Mele Pitia (Fellow). Approx. 10 hours. May 2022 - June 2025.

Kelsi Buraimoh (Fellow). Approx. 10 hours. January 2022 - June 2025.

Jessica Nwabuoku (Fellow). Approx. 10 hours. August 2021 - June 2025.

Komal Parkeh (Fellow). Approx. 10 hours. August 2021 - June 2025.

Shanelle Debraux (Fellow). Approx. 20 hours. August 2021 - June 2025.

Christopher Nguyen (Fellow). Approx. 10 hours. June 2023 - May 2025.

Brittany Phan (Fellow). Approx. 10 hours. June 2023 - January 2025.

Kong Thao (Fellow). Approx. 10 hours. June 2023 - August 2024.

Danielle Boua (Fellow). Approx. 40 hours. June 2023 - June 2024.

Ibthihal Raja (Fellow). Approx. 10 hours. June 2023 - June 2024.

Michael Johnson (Fellow). Approx. 20 hours. June 2023 - June 2024.

Chinedu Ibebuchi (Fellow). Approx. 10 hours. June 2022 - June 2024.

Francesca Joseph (Fellow). Approx. 10 hours. June 2022 - June 2024.

Jihye Park (Fellow). Approx. 20 hours. June 2022 - June 2024.

Liji Tan (Fellow). Approx. 10 hours. June 2022 - June 2024.

Ramon Kelly (Fellow). Approx. 20 hours. June 2022 - June 2024.

Rebecca Mengue (Fellow). Approx. 10 hours. June 2022 - June 2024.

Veeraya White (Fellow). Approx. 10 hours. June 2022 - June 2024.

Ericka Lassiar (Fellow). Approx. 25 hours. May 2022 - June 2024.

Isaac Darkwah (Fellow). Approx. 10 hours. May 2022 - June 2024.

Olubukunola Onajin (Fellow). Approx. 10 hours. May 2022 - June 2024.

Arinze Onwualu (Fellow). Approx. 10 hours. April 2022 - June 2024.

Brianna Whitfield (Fellow). Approx. 20 hours. April 2022 - June 2024.

Yokonha Alleyne (Fellow). Approx. 20 hours. April 2022 - June 2024.

Demetra Anastasiadis (Fellow). Approx. 20 hours. January 2022 - June 2024.

Moozdeleefa Muhammed (Fellow). Approx. 40 hours. January 2022 - June 2024.

DesseyAnn Julian (Fellow). Approx. 40 hours. August 2021 - June 2024.

Gabriel Lake (Fellow). Approx. 20 hours. January 2020 - June 2024.

Letisha Braswell (Fellow). Approx. 10 hours. January 2020 - June 2024.

Simone Nasroodin (Fellow). Approx. 10 hours. June 2023 - March 2024.

Nenna Agamegwa (Fellow). Approx. 10 hours. May 2023 - February 2024.

Ebenezer Tsoedi (Fellow). Approx. 10 hours. May 2022 - October 2023.

Maimun ALam (Fellow). Approx. 20 hours. 2020 - 2022.

Keisha Stubbs (Fellow). Approx. 50 hours. 2019 - 2021.

Seid Suleyman (Fellow). Approx. 40 hours. 2019 - 2021.

Adaobi Anyiwo (Fellow). Approx. 60 hours. 2016 - 2020.

Tanjinatus Oishi (Graduate Student). Approx. 60 hours. 2014 - 2020.

Onyeka Goodwin (Graduate Student). Approx. 90 hours. 2012 - 2018.

## **Non-Credit Instruction Taught**

Guest Lecture, George Washington University, 100 participants. (April 2, 2025 - Present).

Management/Executive Development, Pharmaceutical Industry Partners, 120 participants. (June 19, 2023 - Present).

## **Teaching Innovation and Curriculum Development**

New Course. Pharmacy Law and Policy. January 1, 2023 - June 30, 2025.

This course bridges U.S. health policy and pharmaceutical law, beginning with an overview of the policymaking and legal systems that shape healthcare. It explores key issues in pharmaceutical access and regulation, equipping students to evaluate policy tools and strategies. Emphasis is placed on understanding how coherent pharmaceutical policy supports a functional healthcare system and on analyzing the strengths and limitations of different policy approaches.

Revise Existing Course. Making Medicines. January 3, 2024 - May 8, 2024.

Retooled a detailed and in-depth instruction of the Drug Development Process. Added a scholarly writing component that has improved student engagement and performance.

New Course. Regulatory Writing. January 8, 2022 - June 30, 2023.

I introduced a new course on regulatory writing to strengthen regulatory writing for graduate students. This course is designed to bring the elements of the real world into the classroom. Practitioners are brought to the classroom and they interrogate ongoing material/submissions from the FDA allowing the student to digest a consequential piece of learning. I have collaborated with one of the leading Regulatory Writing firms which has decades of

submission and scholarly publication experience. There is no other course in the curriculum that uses this deep praxis-based approach with data that actually matters to the client.

Revise Existing Course. Pharmacy Jurisprudence. July 30, 2019 - June 30, 2020.

I fully implemented the requirement to have the Pre MPJE as the final exam for the course. The preliminary assessment has shown that students feel better the handling the exam. The state scores have also shown growth in a positive direction (4 %points ahead of the National Average with 2021 scores

Revise Existing Course. Principles of Pharmacy Administration. August 15, 2018 - June 30, 2019.

I revised the course such that Module One focuses on the student's self-development and creates a better foundation as students prepare for Residencies and Fellowships. Students can comprehend the elements necessary to withstand real-world approaches to self-management. The self-development is then applied in Module Two where students develop and Industry professionals grade a heavily weighted Capstone project. The Capstone project asks the students to create a contemporary business plan which uses material presented from across the curriculum to develop the foundation of the business plan. The plan is required to be real and all the steps the students take must be validated in the marketplace. The students work in teams and critique each other. They are given an example outside of the Pharmacy Specialty and are therefore forced to extrapolate their thinking. Questions from each project are covered in the comprehensive final so that the students must understand all the teams' projects.

Students receive feedback from a team of industry professionals immediately upon completion of their presentations. This approach while detailed and deep has proven to be very beneficial to the student's preparation based on the post-graduation placement success.

## **Faculty Development Activities Attended**

Continuing Education Program, "Initiating Buprenorphine: A Comprehensive Training for Pharmacists," American Pharmacist Association, Washington, DC, United States. (October 24, 2024 - October 24, 2027).

Self-Study Program, "Making Medicine/Regulatory Affairs," Eli Lilly and Company. (September 2023 - December 2024).

Self-Study Program, "NIH Principles of Clinical Pharmacology," National Institutes of Health, Bethesda, MD. (September 2023 - June 2024).

Self-Study Program, "Kaiser Permanente Pharmacist Development Series," Kaiser Permanente, Washington, DC, United States. (July 1, 2023 - June 30, 2024).

Live Online Course with Additional Self Study, "Office of Regulatory Affairs & Quality Regulatory Affairs Training Program," Office of Regulatory Affairs and Quality Duke School of Medicine, Durham, NC, United States. (April 12, 2024 - May 17, 2024).

Seminar, "De-Mystifying AI in Healthcare: Common Challenges AI Can Help Solve," Drug Information Association of the Americas, Fort Washington, PA, United States. (January 18, 2024).

Continuing Education Program, "Cultural Competency Focused on Patients or Clients Who Identify as LGBTQ," Howard University. (2023).

Continuing Education Program, "HIV/AIDs & Opportunistic Infection," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "Implicit Bias, Cultural Competence and Culturally and Linguistically Appropriate Services (CLAS) In Health and Health Care," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "Medication and Dispensing Errors," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "Nutrition and Obesity Prevention," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "Responsible Opioid Prescribing and Effective Pain Management," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "Smoking, Vaping, And Tobacco Cessation (Including Dangers of Smoking, and Non-Smoke Tobacco Products)," Howard University, Washington, DC, United States. (2023).

Continuing Education Program, "The Need for and Key Issues in the Application of Implementation Science in Pharmacy Research and Practice," AACP, Orlando, FL, United States. (2023).

Workshop, "AACP Innovate Conference," American Association of Colleges of Pharmacy, Orlando, FL. (February 2023).

Continuing Education Program, ". Developing a Therapeutic Action Plan for MTM," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Assessing and Optimizing Patient Adherence in MTM," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Bone and Joint Diseases," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Cardiovascular Conditions," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Collection and Evaluation of Patient specific Information," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Communication Essentials: Tips for Patient and Caregiver Communication," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Communication With Physicians and Other Healthcare Providers," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Endocrine Disorders," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Gastrointestinal Disorders," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Identifying Patients for MTM Services," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Immunization 101 Vaccines: An Introduction to Vaccinology," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Immunization 102 ACIP-Recommended Vaccines for Adults," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Medication Safety and Error Prevention," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Overview and Definition of Medication Therapy Management (MTM)," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Practicing Evidence-Based Medicine," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Practicing Evidence-Based Medicine," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Psychiatric Disorders," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Respiratory Diseases," Postgraduate Healthcare Education, LLC. (2022).

Continuing Education Program, "Urologic Disorders," Postgraduate Healthcare Education, LLC. (2022).

Attendance/Presentation at American Association of Colleges of Pharmacy Conference, "Influence of Population Genetics and Psychosocial Factors on Pharmacotherapy Case-Based. Where is the Meridian?" American Association of Colleges of Pharmacy, Grapevine, TX, United States. (July 23, 2022 - July 27, 2022).

Conference Attendance, "Drug Information Association Conference," Drug Information Association, Chicago, IL, United States. (June 19, 2022 - June 21, 2022).

Conference Attendance, "APhA Annual Conference. Poster Presentation with Post Doctoral Fellow," American Pharmacist Association. (March 18, 2022 - March 21, 2022).

Seminar, "Giving Voice to Regulatory Leadership," Regulatory Affairs Professional Society, Rockville, MD, United States. (October 5, 2021).

Conference Attendance, "Drug Information Association European Conference," Drug Information Association. (March 15, 2021 - March 19, 2021).

Conference Attendance, "The Teaching Professor Online Conference," Magna Publications. (May 29, 2020 - May 31, 2020).

Faculty Development Program, "Distance Learning Certification," Howard University Center for Teaching Learning and Assessment. (January 2020).

Workshop, "Developing Emotional Intelligence," Pryor Learning Associates, Washington, DC, United States. (January 28, 2020).

Self-Study Program, "Global Regulatory Strategy for Pharmaceuticals," Regulatory Affairs Professional Society, Rockville, MD, United States. (December 10, 2019).

Self-Study Program, "Pharmaceuticals Definition and Lifecycle," Regulatory Affairs Professional Society, Rockville, MD, United States. (December 10, 2019).

Self-Study Program, "Role of the Regulatory Professional," Regulatory Affairs Professional Society, Rockville, MD, United States. (December 10, 2019).

Faculty Development, "Harassment and Discrimination Prevention Certification Training," Howard University. (November 2019).

Continuing Education Program, "Howard University Opioid Symposium and Naloxone Administration Training for Pharmacy Professionals," Howard University College of Pharmacy/FDA. (September 2019).

Workshop, "The Revised Common Rule," Howard University Hospital. (February 19, 2019).

Self-Study Program, "Medical Devices: Definition and Lifecycle," Regulatory Affairs Professional Society, Rockville, MD, United States. (December 11, 2018).

American Association of College of Pharmacy Annual Meeting, "Interdisciplinary Approaches to Combating the Opioid Use Disorder Epidemic: Lessons Learned from Howard University.," American Association of Colleges of Pharmacy, Boston, MA. (July 2018).

Seminar, "American Pharmacists Association Annual Meeting," San Francisco, CA. (March 2017).

Faculty Development Program, "Provost/RCMI Faculty Mentoring Program," Office of the Provost Howard University, Washington, DC. (January 2017 - March 2017).

Research Related Conference/Seminar, "Georgetown University Mentoring for Clinical and Translational Researchers," Washington, DC. (February 2017).

Research Related Conference/Seminar, "Clinical Investigator Training," Silver Spring, MD. (November 2016).

Research Related Conference/Seminar, "Academy Health Concordia Meeting," Arlington, VA. (September 2016).

Seminar, "Center for Medicare and Medicaid Services," Baltimore, MD. (September 2016).

## **University Service**

Member, PIRC Committee-- Program Innovation and Review Committee. (August 28, 2024 - Present).

Member, Judiciary Committee. (June 2023 - Present).

Member of Executive Council, Center for Women Gender and Global Leadership. (December 2020 - Present).

Member, Promotions and Tenure Committee. (August 27, 2018 - Present).

Co-Chairman, Medical IRB. (August 1, 2017 - Present).

Member, College of Pharmacy Executive Committee. (2017 - Present).

Member, Research Development and Graduate Programs. (October 6, 2013 - Present).

Committee Lead/Member, President's Committee to Establish an Office of Global & Diaspora Engagement (GDE). (March 2024 - July 2024).

Chair, American Council on Pharmaceutical Education (ACPE) Self-Study Accreditation Team. (2019 - 2021).

Chair, College of Nursing and Allied Health Sciences Department of Physical Therapy Chairman Search Committee. (2019 - 2020).

Member, National Human Genome Center Director Search Advisory Committee, Member, National Human Genome Center Director Search Advisory Committee. (2018 - 2020).

Member, Innovation and Entrepreneurship. (October 2, 2016 - 2020).

Member, Standing Committee on Admission, Recruitment and Retention. (October 7, 2012 - 2020).

Chairman, Academic Progression and Retention. (October 1, 2018 - August 2020).

Member, Student Grievance Committee. (October 6, 2013 - 2019).

Member, Curriculum, Instructional and Resources Committee. (October 7, 2012 - 2019).

Member College of Dentistry Dean Search Committee, University. (2018).

Member, IRB. (January 15, 2014 - July 31, 2017).

## **Professional Service**

Editorial Review Board Member, African Journal of Rhetoric, Die Hoewes, Centurion. (March 2020 - Present).

Reviewer/Referee, Pharmacogenomics, London. (December 7, 2019 - Present).

Reviewer/Referee, Journal of the American Pharmacists Association, Oxford. (December 2018 - Present).

Team Leader, National Association of Chain Drug Stores (NACDS) RxIMPACT "U", Alexandria, VA. (March 2009 - Present).

## **Public Service**

Volunteer, Hope Christian Church Protocol, Beltsville, MD. (July 2004 - Present).

Board Member, Healthy Families DC, Washington, DC. (September 1997 - July 2007).

Board Member, DC Healthy Families, Washington, DC. (April 27, 1998 - June 30, 2007).